Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study

Abstract

This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.

DOI: 10.1007/BF00873920

1 Figure or Table

Cite this paper

@article{Chapman1993MitogauzoneCA, title={Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study}, author={Robert Chapman and John Crowley and Joel G. Lucas and Ben Lin Hom and Robert B . Livingston and Clarence B. Vaughn and Harry E. Hynes}, journal={Investigational New Drugs}, year={1993}, volume={11}, pages={91-92} }